People: CRISPR Therapeutics AG (CRSP.OQ)
15 Nov 2019
Dr. Jon Terrett, Ph.D., serves as Head of Immuno-Oncology Research and Translation at CRISPR Therapeutics Ltd. Prior to joining CRISPR Therapeutics, he was the Vice President of oncology discovery for CytomX, a U.S.-based biotechnology company focused on developing drugs to treat different types of cancer. In addition, he has held various R&D leadership roles in biopharma, including serving as the Chief Scientific Officer at Oxford Biotherapeutics, and as a director at various biotechnology companies including Medarex, CellTech and Oxford Glycosciences. He received a B.S. in genetics at the University of Sheffield and a doctorate in genetics at the University of Nottingham.
|Total Annual Compensation,||--|
|Restricted Stock Award,||--|
|Long-Term Incentive Plans,||--|
|Fiscal Year Total,||--|